Patent ID: 11897927
Assignee: ADVAXIS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 40:
41. The recombinant Listeria strain of claim 40, wherein:
(a) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: KRAS\, EGFR, U2AF1, BRAF, PIK3CA, and TP53;
(b) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: SPOP, CHEK2, RGPD8, ANKRD36C, and AR;
(c) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: KRAS\, U2AF1, TP53, SMAD4, and GNAS;
(d) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: PIK3CA, FGFR3, TP53, RXRA, FBXW7, and NFE2L2;
(e) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: PIK3CA, AKT1, and ESR1;
(f) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: PTEN, KRAS\, PIK3CA, CTNNB1, FBXW7, and TP53;
(g) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: TP53;
(h) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: TP53, PIK3CA, IDH1, IDH2, and EGFR;
(i) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: KRAS\, BRAF, PIK3CA, and TP53; or
(j) the antigenic peptides comprise recurrent cancer mutations from proteins encoded by one or more or all of the following genes: PIK3CA, CHEK2, RGPD8, ANKRD36C, TP53, ZNF814, KRTAP1-5, KRTAP4-11, and HRAS.